Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com
A00023 | Pages: 360 | Charts: 78 | Tables: 167 |
The global flow cytometry market size was valued at $6.2 billion in 2022, and is projected to reach $16.6 billion by 2032, growing at a CAGR of 10.3% from 2023 to 2032. The flow cytometry market growth is driven by augmented R&D investments from companies operating in the life sciences industry. According to the Savills India Report, venture capital funding into the life sciences industry in India was $448 million in August 2021. It was almost 3 times the annual average for the last five years. It was attributed to potential opportunities in drug discovery and medical devices. The cytometry industry is an attractive investment space, owing to many patent expirations of flow cytometry devices and increasing applications of flow cytometry in various diseases.
Flow cytometry is a biophysical, laser-based analytical technology, which is used to measure and analyze cells in a fluid system. Cells under analysis are labelled using fluorescent techniques and then excited using laser to emit light at different wavelengths to analyze characteristics of cells or particles. During the process, a sample of cells or particles is suspended in fluid and injected into a flow cytometer machine. Approximately 10,000 cells are analyzed and processed by a computer in less than one minute.
The flow cytometry market expansion is significantly driven by rise in incidence of diseases such as HIV and blood disorders, with the technology playing a crucial role in diagnosis and treatment monitoring. According to the World Health Organization (WHO), approximately 37.7 million people were living with HIV globally in 2020, with over two-thirds (25.4 million) residing in the African Region. In addition, 1.5 million people acquired HIV in 2020, and 68 million died from HIV-related causes. Flow cytometry is particularly valuable in these regions due to its precision in diagnosing HIV, tracking disease progression, and monitoring treatment responses, which helps reduce the disease burden. Rise in population and increase in health awareness in developing economies further boost market growth, as these regions adopt advanced diagnostic technologies to manage widespread diseases.
Moreover, flow cytometry is widely used across various fields including clinical and healthcare applications, genomics, proteomics, marine biology, microbiology, environmental sciences, and molecular cytogenetics. In genomics, it is used for detecting genetic disorders, genotyping, and mRNA typing. Its ability to perform multiplex arrays enables efficient genetic analysis and identification of specific microbes or subtypes, critical for diagnosing complex conditions. In proteomics, the technology is used for protein structure analysis, quantification, and studying metabolic pathways, growth factors, and cytokines. Its applications extend to DNA/RNA analysis, cell viability assays, metabolic disease analysis, and vaccine development, thereby supporting advanced gene expression research. Flow cytometry instruments, paired with high-specification lasers and optical systems, provide high-speed, high-resolution analysis of small samples in microarrays, driving significant advancements in biosciences.
However, the market faces challenges, notably the high cost of instruments and reagents, which hinder widespread adoption. These instruments require substantial capital investment for setup and maintenance, with prices varying based on size, technology, and features. Reagents used for staining in flow cytometry are also expensive, particularly in diagnostic applications, adding to the overall cost. These financial barriers limit the growth potential of the flow cytometry market, especially in regions with constrained healthcare budgets. Despite these challenges, the technology's increasing use in research and diagnostics continues to drive market expansion.
The flow cytometry market is segmented into component, technology, application, end user, and region. By component, the flow cytometry market is classified into instruments, reagents & consumables, software, and services. The instrument segment is further divided into platforms, replaceable components, and accessories. The platforms segment is further categorized into sorters and analyzers. Filters, lasers, detectors, and others are considered as types of replaceable components. The reagents market is further divided into antibodies, dyes, beads, and others. On the basis of technology, the market is bifurcated into cell-based flow cytometry and bead-based flow cytometry.
On the basis of application, it is categorized into academic & clinical applications and diagnostic applications. The academic & clinical applications segment is further divided into cell cycle analysis & cell proliferation, apoptosis, cell sorting, transfect ion & cell viability, and others. The diagnostic applications segment is further segmented into organ transplantation, hematological malignancies, HIV, solid tumors & cancer, and others. On the basis of end user, the market is categorized into hospitals, medical schools & clinical testing labs, commercial organizations, academic institutions, and others. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The instruments segment dominated the market share in 2022, owing to development of novel instrument designs, demand for highly efficient replaceable components, applications in treatment of newer diseases, and increase in research & developments in flow cytometry techniques. Reagents & consumables are expected to emerge as the leading segment as they are essentials in flow cytometry analysis. In addition, combination of imaging capabilities and instruments further boost instrument performance and make it more accessible to emerging economies.
The cell-based flow cytometry segment dominated the market share in 2022, owing to its ability to analyze and quantify multiple cellular parameters simultaneously. This technology is widely used in immunology, cancer research, and drug development, offering high accuracy and efficiency.
However, the bead-based flow cytometry segment is expected to exhibit the fastest CAGR growth during the forecast period, owing to its wide scale use in research applications, lesser time consumption, and simultaneous analysis of multiple samples. However, the cell-based flow cytometry segment is the highest revenue generating segment, owing to its wide scale application in the diagnosis of various diseases such as cancer and HIV, biomedical research, and its increasing use in monitoring the progress of drug treatment.
The academic & clinical applications segment held the largest flow cytometry market share in 2022, owing to the increase in demand for advanced diagnostic tools in research and clinical settings. Flow cytometry plays a crucial role in immunology, oncology, and hematology, enabling precise cell analysis and supporting disease diagnosis, drug discovery, and biomarker identification.
However, the diagnostic applications segment is expected to witness considerable growth during the forecast period, owing to the increasing adoption of flow cytometry in disease diagnosis, particularly in oncology, immunology, and hematology. Its ability to provide accurate, rapid, and multiplexed cell analysis for detecting abnormalities, monitoring disease progression, and assessing treatment response is driving its growing use in clinical diagnostics.
The commercial organizations segment held the largest flow cytometry market share in 2022, owing to the widespread adoption of flow cytometry by pharmaceutical and biotechnology companies for drug discovery, clinical trials, and personalized medicine development. These organizations utilize flow cytometry for its high-throughput capabilities, precise cell analysis, and ability to support complex research, driving significant demand in commercial settings.
The flow cytometry industry is analyzed across North America, Europe, Asia-Pacific, LAMEA. North America dominated the market share in 2022. This dominance is attributed to advanced healthcare infrastructure, high research and development investments, and strong adoption of cutting-edge technologies such as flow cytometry in clinical and academic settings. In addition, the region's well-established pharmaceutical industry contributed to market growth.
However, the Asia-Pacific region is anticipated to register the highest CAGR during the forecast period. This is attributed to expanding healthcare infrastructure, increasing research activities, rising prevalence of chronic diseases, and growing investments in biotechnology and pharmaceutical sectors in emerging economies.
Agilent Technologies, Inc., Becton Dickinson and Company, bioMérieux SA, have adopted product launch, collaboration, partnership as key developmental strategies to improve the product portfolio of the flow cytometry market. For instance, In August 2022, Becton, Dickinson, and Company announced a collaboration agreement with Labcorp. The collaboration aimed to create a framework to develop, manufacture, market and commercialize flow cytometry-based companion diagnostics (CDx) intended to match patients with life-changing treatments for cancer and other diseases.